134 related articles for article (PubMed ID: 35092841)
1. Improving Outcomes in NSCLC: Optimum Dose Fractionation in Radical Radiotherapy Matters.
Brada M; Forbes H; Ashley S; Fenwick J
J Thorac Oncol; 2022 Apr; 17(4):532-543. PubMed ID: 35092841
[TBL] [Abstract][Full Text] [Related]
2. Dose escalation of accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in unresectable stage III non-small-cell lung cancer: a phase I trial.
Lin Q; Liu YE; Ren XC; Wang N; Chen XJ; Wang DY; Zong J; Peng Y; Guo ZJ; Hu J
Radiat Oncol; 2013 Aug; 8(1):201. PubMed ID: 23957889
[TBL] [Abstract][Full Text] [Related]
3. High-dose accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in locally advanced non-small-cell lung cancer: a feasibility study.
Liu YE; Lin Q; Meng FJ; Chen XJ; Ren XC; Cao B; Wang N; Zong J; Peng Y; Ku YJ; Chen Y
Radiat Oncol; 2013 Aug; 8(1):198. PubMed ID: 23937855
[TBL] [Abstract][Full Text] [Related]
4. Survival Outcomes of Post-mastectomy Breast Cancer Patients Treated with Hypofractionated Radiation Treatment Compared to Conventional Fractionation -a Retrospective Cohort Study.
Raveendran C; Meloot SS; Yadev I
Gulf J Oncolog; 2023 May; 1(42):26-34. PubMed ID: 37283257
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic Ablative Body Radiotherapy Versus Radical Radiotherapy: Comparing Real-World Outcomes in Stage I Lung Cancer.
Phillips I; Sandhu S; Lüchtenborg M; Harden S
Clin Oncol (R Coll Radiol); 2019 Oct; 31(10):681-687. PubMed ID: 31377081
[TBL] [Abstract][Full Text] [Related]
6. Improving outcomes in non-small cell lung cancer; population analysis of radical radiotherapy.
Brada M; Ball C; Mitchell S; Forbes H; Ashley S
Radiother Oncol; 2019 Mar; 132():204-210. PubMed ID: 30392781
[TBL] [Abstract][Full Text] [Related]
7. Hypofractionated vs. conventional radiation therapy for stage III non-small cell lung cancer treated without chemotherapy.
Iocolano M; Wild AT; Hannum M; Zhang Z; Simone CB; Gelblum D; Wu AJ; Rimner A; Shepherd AF
Acta Oncol; 2020 Feb; 59(2):164-170. PubMed ID: 31608751
[No Abstract] [Full Text] [Related]
8. Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial.
Sundstrøm S; Bremnes R; Aasebø U; Aamdal S; Hatlevoll R; Brunsvig P; Johannessen DC; Klepp O; Fayers PM; Kaasa S
J Clin Oncol; 2004 Mar; 22(5):801-10. PubMed ID: 14990635
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of accelerated radiotherapy for patients with inoperable non-small cell lung cancer (NSCLC) and borderline prognostic factors without distant metastasis: a retrospective review.
Nguyen LN; Komaki R; Allen P; Schea RA; Milas L
Int J Radiat Oncol Biol Phys; 1999 Jul; 44(5):1053-6. PubMed ID: 10421538
[TBL] [Abstract][Full Text] [Related]
10. Comparison of hypofractionation and standard fractionation for post-prostatectomy salvage radiotherapy in patients with persistent PSA: single institution experience.
Murgic J; Jaksic B; Prpic M; Kust D; Bahl A; Budanec M; Prgomet Secan A; Franco P; Kruljac I; Spajic B; Babic N; Kruslin B; Zovak M; Zubizarreta E; Rosenblatt E; Fröbe A
Radiat Oncol; 2021 May; 16(1):88. PubMed ID: 33980277
[TBL] [Abstract][Full Text] [Related]
11. Accelerated hypofractionated three-dimensional conformal radiation therapy (3 Gy/fraction) combined with concurrent chemotherapy for patients with unresectable stage III non-small cell lung cancer: preliminary results of an early terminated phase II trial.
Ren XC; Wang QY; Zhang R; Chen XJ; Wang N; Liu YE; Zong J; Guo ZJ; Wang DY; Lin Q
BMC Cancer; 2016 Apr; 16():288. PubMed ID: 27108080
[TBL] [Abstract][Full Text] [Related]
12. Assessment of Toxic Effects Associated With Dose-Fractionated Radiotherapy Among Patients With Cancer and Comorbid Collagen Vascular Disease.
Yoon SM; Chu FI; Ruan D; Steinberg ML; Raldow A; Lee P
JAMA Netw Open; 2021 Feb; 4(2):e2034074. PubMed ID: 33599771
[TBL] [Abstract][Full Text] [Related]
13. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
Widmark A; Gunnlaugsson A; Beckman L; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Fransson P; Tavelin B; Norman D; Zackrisson B; Anderson H; Kjellén E; Franzén L; Nilsson P
Lancet; 2019 Aug; 394(10196):385-395. PubMed ID: 31227373
[TBL] [Abstract][Full Text] [Related]
14. Accelerated radical radiotherapy for non-small cell lung cancer using two common regimens: a single-centre retrospective study of outcome.
Pemberton LS; Din OS; Fisher PM; Hatton MQ
Clin Oncol (R Coll Radiol); 2009 Apr; 21(3):161-7. PubMed ID: 19111452
[TBL] [Abstract][Full Text] [Related]
15. Unresected stage III non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group.
Okawara G; Rusthoven J; Newman T; Findlay B; Evans W
Cancer Prev Control; 1997 Aug; 1(3):249-59. PubMed ID: 9765750
[TBL] [Abstract][Full Text] [Related]
16. Non-small cell lung cancer in stages I-IIIB: Long-term results of definitive radiotherapy with doses ≥ 80 Gy in standard fractionation.
Wurstbauer K; Weise H; Deutschmann H; Kopp P; Merz F; Studnicka M; Nairz O; Sedlmayer F
Strahlenther Onkol; 2010 Oct; 186(10):551-7. PubMed ID: 20936459
[TBL] [Abstract][Full Text] [Related]
17. Dose-per-fraction escalation of accelerated hypofractionated three-dimensional conformal radiotherapy in locally advanced non-small cell lung cancer.
Kepka L; Tyc-Szczepaniak D; Bujko K
J Thorac Oncol; 2009 Jul; 4(7):853-61. PubMed ID: 19487965
[TBL] [Abstract][Full Text] [Related]
18. External beam radiation dose escalation for high grade glioma.
Khan L; Soliman H; Sahgal A; Perry J; Xu W; Tsao MN
Cochrane Database Syst Rev; 2020 May; 5(5):CD011475. PubMed ID: 32437039
[TBL] [Abstract][Full Text] [Related]
19. Accelerated Hypofractionated Image-Guided vs Conventional Radiotherapy for Patients With Stage II/III Non-Small Cell Lung Cancer and Poor Performance Status: A Randomized Clinical Trial.
Iyengar P; Zhang-Velten E; Court L; Westover K; Yan Y; Lin MH; Xiong Z; Patel M; Rivera D; Chang J; Saunders M; Shivnani A; Lee A; Hughes R; Gerber D; Dowell J; Gao A; Heinzerling J; Li Y; Ahn C; Choy H; Timmerman R
JAMA Oncol; 2021 Oct; 7(10):1497-1505. PubMed ID: 34383006
[TBL] [Abstract][Full Text] [Related]
20. Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials.
Choudhury A; Porta N; Hall E; Song YP; Owen R; MacKay R; West CML; Lewis R; Hussain SA; James ND; Huddart R; Hoskin P;
Lancet Oncol; 2021 Feb; 22(2):246-255. PubMed ID: 33539743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
